Michael Owens
Direttore Finanziario/CFO presso ONCOZENGE AB
Provenienza dei contatti di primo grado di Michael Owens
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 19 | |
| Public Company | Financial Conglomerates | 17 | |
| Public Company | Miscellaneous Commercial Services | 8 | |
| Public Company | Electronic Equipment/Instruments | 8 | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.
8
| Holding Company | Pharmaceuticals: Major | 8 |
| Public Company | Pharmaceuticals: Major | 5 | |
Dizlin Pharmaceuticals AB
2
| Private Company | 2 | |
Emollivet AB
1
| Private Company | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Michael Owens tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| BIOGAIA AB | Pharmaceuticals: Other | Director of Finance/CFO Founder Chief Tech/Sci/R&D Officer Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Operating Officer | |
| University of London | College/University | Doctorate Degree Undergraduate Degree | |
| Chalmers University of Technology | College/University | Graduate Degree Director/Board Member Graduate Degree Undergraduate Degree | |
| Stockholm School of Economics | College/University | Undergraduate Degree Undergraduate Degree Masters Business Admin Masters Business Admin Undergraduate Degree | |
| University of Uppsala | College/University | Masters Business Admin Graduate Degree Corporate Officer/Principal Graduate Degree Masters Business Admin Doctorate Degree | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chief Executive Officer Private Equity Investor Chief Executive Officer Private Equity Investor Private Equity Investor Private Equity Analyst | |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member President | |
| Royal Institute of Technology | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| University of Lund | College/University | Corporate Officer/Principal Corporate Officer/Principal Graduate Degree | |
| NAVAMEDIC ASA | Medical Distributors | Director/Board Member Director of Finance/CFO Chief Executive Officer | |
| University of Gothenburg | College/University | Corporate Officer/Principal Graduate Degree | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chief Administrative Officer Chief Executive Officer | |
| Astra Arcus AB | Corporate Officer/Principal Corporate Officer/Principal | ||
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Director/Board Member Corporate Officer/Principal Chief Executive Officer | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| XSPRAY PHARMA AB | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| KCIF Fund Management AB | Director/Board Member Chief Executive Officer Chief Executive Officer Chairman | ||
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor Chairman | |
| NEOS AB | Medical Specialties | Chairman Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Investor Relations Contact Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| SPRINT BIOSCIENCE AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO | |
| INHALATION SCIENCES SWEDEN AB | Medical Specialties | Director of Finance/CFO Chief Executive Officer Director/Board Member | |
| DIAMYD MEDICAL AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
TwoPac AB
 TwoPac AB Chemicals: Major DiversifiedProcess Industries Part of BioGaia AB, TwoPac AB is a Swedish company that manufactures and develops probiotic drops and related packaging products. The company is based in Eslöv, Sweden. TwoPac was acquired by BioGaia AB on July 01, 2013 for $4.64 million. | Chemicals: Major Diversified | Director/Board Member Director/Board Member | |
Betagenon Sweden AB
 Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Chief Executive Officer Analyst-Equity | |
CapAble AB
 CapAble AB Containers/PackagingProcess Industries Part of BioGaia AB, CapAble AB is a Swedish company that manufactures and sells plastic packaging products. The company is based in Stockholm, Sweden. | Containers/Packaging | Director/Board Member Chairman | |
Twopac Laboratories AB
 Twopac Laboratories AB Miscellaneous Commercial ServicesCommercial Services Twopac Laboratories AB engages in technology, research, and development activities. The private company is based in Eslov, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Twopac Machine AB
 Twopac Machine AB Industrial MachineryProducer Manufacturing Twopac Machine AB is a Swedish company that manufactures machinery products. The private company is based in Eslöv, Sweden. | Industrial Machinery | Director/Board Member Chairman | |
| Betagenon Bio AB | Director/Board Member Chairman | ||
Amplifier TX AB
 Amplifier TX AB BiotechnologyHealth Technology Part of Cambrian BioPharma, Inc., Amplifier TX AB is a Swedish biopharmaceutical company that develops clinical molecule AMPK activators. The private company is based in Umeå, Sweden. The company was founded in 2023 by Thomas Edlund, Helena Edlund. James Hall has been the CEO of the company since 2023. | Biotechnology | Director/Board Member Chief Executive Officer |
Statistiche
Distribuzione geografica
| Svezia | 47 |
| Regno Unito | 3 |
| Norvegia | 3 |
Settori
| Health Technology | 27 |
| Consumer Services | 9 |
| Commercial Services | 8 |
| Finance | 3 |
| Process Industries | 3 |
Posizioni
| Director/Board Member | 314 |
| Corporate Officer/Principal | 114 |
| Chairman | 92 |
| Chief Executive Officer | 54 |
| Independent Dir/Board Member | 53 |
Contatti più connessi
| Insiders | |
|---|---|
| Peter Sjöstrand | 35 |
| Stig Lennart Hansson | 32 |
| Michael Wilhelm Rosenlew | 32 |
| Sten Gunnar Otto Skolling | 32 |
| Carl Johan Kördel | 31 |
| Torbjørn Bjerke | 27 |
| Anders Olof Adolf Ekblom | 27 |
| Peter Michael Rothschild | 24 |
| Terje Kalland | 20 |
| Gunilla Lundmark | 20 |
| Carl Harald Janson | 19 |
| Ray Hill | 18 |
| Per Nilsson | 17 |
| Hans-Peter Torsten Ekre | 16 |
| Staffan Schüberg | 15 |
- Borsa valori
- Insiders
- Michael Owens
- Connessioni Società
